195611-82-6 Usage
General Description
GW7604 is a synthetic compound that acts as a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). It is a member of the thiazolidinedione class of drugs, which are known for their ability to improve insulin sensitivity and lipid metabolism. GW7604 has been shown to have anti-inflammatory, anti-atherogenic, and anti-diabetic effects in preclinical studies, making it a potential candidate for the treatment of metabolic disorders such as type 2 diabetes and dyslipidemia. Additionally, it has been investigated for its potential as a therapeutic agent in the treatment of cancer, as PPARδ activation has been shown to inhibit the proliferation and metastasis of various cancer cell lines. Overall, GW7604 exhibits promising pharmacological properties that make it a potentially valuable compound for the treatment of various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 195611-82-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,5,6,1 and 1 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 195611-82:
(8*1)+(7*9)+(6*5)+(5*6)+(4*1)+(3*1)+(2*8)+(1*2)=156
156 % 10 = 6
So 195611-82-6 is a valid CAS Registry Number.
195611-82-6Relevant articles and documents
Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators
Baecker, Daniel,Gaggia, Francesca,Gust, Ronald,Kalchschmid, Christina,Knox, Alexandra,Manzl, Claudia,Schuster, Daniela
, (2020/03/13)
Up to 80% of mammary carcinoma initially exhibit estrogen-dependent growth, which can be treated by aromatase inhibitors or SERMs/SERDs. To increase the options after failure of the hormonal therapy with these drugs, the search for alternatives with a dif
